Clinical Trial: Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults

U.S., March 8 -- ClinicalTrials.gov registry received information related to the study (NCT06863142) titled 'Evaluating the Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRCFLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults' on March 06.

Brief Summary: Background:

Vaccines help the body learn to fight infections. Some vaccines are combined with adjuvants, which are added substances that make vaccines work better. FluMos-v2 is an experimental flu vaccine; ALFQ is an experimental adjuvant.

Objective:

To test FluMos-v2, with and without the ALFQ adjuvant, in healthy adults.

Eligibility:

Healthy adults aged 18 to 50 years. They must have received at least one flu vaccine f...